{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:16:29Z","timestamp":1792808189412,"version":"4.5.0"},"reference-count":59,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,4,7]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed\/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, more than half of patients relapse after CAR-T or TCE therapy, with antigen escape or lineage switching accounting for one-third of disease recurrences. To minimize tumor escape, dual-targeting CAR-T cell therapies simultaneously targeting CD19 and CD22 have been developed and validated both preclinically and clinically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have generated the first dual-targeting strategy for B-cell malignancies based on CD22 CAR-T cells secreting an anti-CD19 TCE antibody (CAR-STAb-T) and conducted a comprehensive preclinical characterization comparing its therapeutic potential in B-ALL with that of previously validated dual-targeting CD19\/CD22 tandem CAR cells (TanCAR-T cells) and co-administration of two single-targeting CD19 and CD22 CAR-T cells (pooled CAR-T cells).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrate that CAR-STAb-T cells efficiently redirect bystander T cells, resulting in higher cytotoxicity of B-ALL cells than dual-targeting CAR-T cells at limiting effector:target ratios. Furthermore, when antigen loss was replicated in a heterogeneous B-ALL cell model, CAR-STAb T cells induced more potent and effective cytotoxic responses than dual-targeting CAR-T cells in both short- and long-term co-culture assays, reducing the risk of CD19-positive leukemia escape. In vivo, CAR-STAb-T cells also controlled leukemia progression more efficiently than dual-targeting CAR-T cells in patient-derived xenograft mouse models under T cell-limiting conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD22 CAR-T cells secreting CD19 T-cell engagers show an enhanced control of B-ALL progression compared with CD19\/CD22 dual CAR-based therapies, supporting their potential for clinical testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009048","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:25:09Z","timestamp":1746055509000},"page":"e009048","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1099-2018","authenticated-orcid":false,"given":"Javier","family":"Arroyo-R\u00f3denas","sequence":"first","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Falgas","sequence":"additional","affiliation":[{"name":"Josep Carreras Leukaemia Research Institute, Barcelona, Spain"},{"name":"Red Espa\u00f1ola de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9545-6910","authenticated-orcid":false,"given":"Laura","family":"D\u00edez-Alonso","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Martinez-Moreno","sequence":"additional","affiliation":[{"name":"Josep Carreras Leukaemia Research Institute, Barcelona, Spain"},{"name":"Red Espa\u00f1ola de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleia","family":"Roca-Ho","sequence":"additional","affiliation":[{"name":"Josep Carreras Leukaemia Research Institute, Barcelona, Spain"},{"name":"Red Espa\u00f1ola de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Gil-Etayo","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"P\u00e9rez-Pons","sequence":"additional","affiliation":[{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca, Salamanca, Spain"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda (CIBERONC; CB16\/12\/00400), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Aguilar-Sope\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain"},{"name":"Lymphocyte Immunobiology Group, Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre (i+12), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Velasco-Sidro","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"G\u00f3mez-Rosel","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3217-6536","authenticated-orcid":false,"given":"Beatriz","family":"Jim\u00e9nez-Mat\u00edas","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Mu\u00f1oz-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Servicio de Inmunolog\u00eda, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedra","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bravo-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain"},{"name":"Lymphocyte Immunobiology Group, Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre (i+12), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Ram\u00edrez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Jim\u00e9nez-Reinoso","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Europa Azucena","family":"Gonz\u00e1lez-Navarro","sequence":"additional","affiliation":[{"name":"Servicio de Inmunolog\u00eda, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-1648","authenticated-orcid":false,"given":"Manel","family":"Juan","sequence":"additional","affiliation":[{"name":"Red Espa\u00f1ola de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Servicio de Inmunolog\u00eda, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca, Salamanca, Spain"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda (CIBERONC; CB16\/12\/00400), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Blanco","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Roda-Navarro","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain"},{"name":"Lymphocyte Immunobiology Group, Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre (i+12), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bueno","sequence":"additional","affiliation":[{"name":"Josep Carreras Leukaemia Research Institute, Barcelona, Spain"},{"name":"Red Espa\u00f1ola de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda (CIBERONC; CB16\/12\/00400), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Men\u00e9ndez","sequence":"additional","affiliation":[{"name":"Josep Carreras Leukaemia Research Institute, Barcelona, Spain"},{"name":"Red Espa\u00f1ola de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda (CIBERONC; CB16\/12\/00400), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats (ICREA), Barcelona, Spain"},{"name":"Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3053-6757","authenticated-orcid":false,"given":"Luis","family":"\u00c1lvarez-Vallina","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Immuno-Oncology and Immunotherapy Group, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain"},{"name":"H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"},{"name":"CNIO-HMRIB Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Hospital del Mar Research Institute Barcelona (HMRIB), Madrid\/Barcelona, Spain"},{"name":"Banc de Sang i Teixits (BST), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"2025103115050509000_13.4.e009048.1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301"},{"key":"2025103115050509000_13.4.e009048.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025103115050509000_13.4.e009048.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025103115050509000_13.4.e009048.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025103115050509000_13.4.e009048.5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed\/Refractory Malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"2025103115050509000_13.4.e009048.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"2025103115050509000_13.4.e009048.7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783"},{"key":"2025103115050509000_13.4.e009048.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2025103115050509000_13.4.e009048.9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hon.3036","article-title":"Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies","volume":"40","author":"Yang","year":"2022","journal-title":"Hematol Oncol"},{"key":"2025103115050509000_13.4.e009048.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"2025103115050509000_13.4.e009048.11","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/10428194.2023.2232496","article-title":"Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R\/R BCP acute lymphoblastic leukemia: a review","volume":"64","author":"Locatelli","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"2025103115050509000_13.4.e009048.12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"2025103115050509000_13.4.e009048.13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"2025103115050509000_13.4.e009048.14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025103115050509000_13.4.e009048.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"key":"2025103115050509000_13.4.e009048.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014840"},{"key":"2025103115050509000_13.4.e009048.17","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol"},{"key":"2025103115050509000_13.4.e009048.18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"2025103115050509000_13.4.e009048.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009432"},{"key":"2025103115050509000_13.4.e009048.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.006"},{"key":"2025103115050509000_13.4.e009048.21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol Ther"},{"key":"2025103115050509000_13.4.e009048.22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178403","article-title":"A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells","volume":"14","author":"Fergusson","year":"2023","journal-title":"Front Immunol"},{"key":"2025103115050509000_13.4.e009048.23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","article-title":"Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma","volume":"9","author":"de Oliveira Canedo","year":"2025","journal-title":"Blood Adv"},{"key":"2025103115050509000_13.4.e009048.24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"2025103115050509000_13.4.e009048.25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"2025103115050509000_13.4.e009048.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.01.008"},{"key":"2025103115050509000_13.4.e009048.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002"},{"key":"2025103115050509000_13.4.e009048.28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0127"},{"key":"2025103115050509000_13.4.e009048.29","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000161397.96582.59"},{"key":"2025103115050509000_13.4.e009048.30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.10.7028"},{"key":"2025103115050509000_13.4.e009048.31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000896","article-title":"Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope","volume":"8","author":"Velasco-Hernandez","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025103115050509000_13.4.e009048.32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020403","article-title":"Nanobody Based Dual Specific CARs","volume":"19","author":"De Munter","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025103115050509000_13.4.e009048.33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01792","article-title":"Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies","volume":"11","author":"Blanco","year":"2020","journal-title":"Front Immunol"},{"key":"2025103115050509000_13.4.e009048.34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2016.391","article-title":"Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors","volume":"31","author":"Aldoss","year":"2017","journal-title":"Leukemia"},{"key":"2025103115050509000_13.4.e009048.35","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2008-0831"},{"key":"2025103115050509000_13.4.e009048.36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-21-0853","article-title":"Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers","volume":"10","author":"Blanco","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025103115050509000_13.4.e009048.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005333","article-title":"Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers","volume":"10","author":"Jim\u00e9nez-Reinoso","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025103115050509000_13.4.e009048.38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054106","article-title":"Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies","volume":"11","author":"Ram\u00edrez-Fern\u00e1ndez","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025103115050509000_13.4.e009048.39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7962","article-title":"Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo","volume":"16","author":"D\u00edez-Alonso","year":"2024","journal-title":"Sci Transl Med"},{"key":"2025103115050509000_13.4.e009048.40","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.38","article-title":"Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025103115050509000_13.4.e009048.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741058"},{"key":"2025103115050509000_13.4.e009048.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2025103115050509000_13.4.e009048.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"2025103115050509000_13.4.e009048.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1"},{"key":"2025103115050509000_13.4.e009048.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.011"},{"key":"2025103115050509000_13.4.e009048.46","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochem Biophys Rep"},{"key":"2025103115050509000_13.4.e009048.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006863","article-title":"BiTE secretion by adoptively transferred stem-like T cells improves FR\u03b1+ ovarian cancer control","volume":"11","author":"McGray","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025103115050509000_13.4.e009048.48","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202206856","article-title":"BiTE-Secreting CAR-\u03b3\u03b4T as a Dual Targeting Strategy for the Treatment of Solid Tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2025103115050509000_13.4.e009048.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53265-7","article-title":"Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors","volume":"15","author":"Rom\u00e1n Alonso","year":"2024","journal-title":"Nat Commun"},{"key":"2025103115050509000_13.4.e009048.50","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T Cells Secreting Anti-FAP\/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025103115050509000_13.4.e009048.51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"2025103115050509000_13.4.e009048.52","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s13402-024-00971-5","article-title":"A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells","volume":"47","author":"Yan","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"2025103115050509000_13.4.e009048.53","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.102015","article-title":"A protocol for collection and infusion of cerebrospinal fluid in mice","volume":"4","author":"Kaur","year":"2023","journal-title":"STAR Protoc"},{"key":"2025103115050509000_13.4.e009048.54","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/cas.14799","article-title":"Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies","volume":"112","author":"Guo","year":"2021","journal-title":"Cancer Sci"},{"key":"2025103115050509000_13.4.e009048.55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2020.07.002","article-title":"Improving CAR T-cells: The next generation","volume":"57","author":"Marple","year":"2020","journal-title":"Semin Hematol"},{"key":"2025103115050509000_13.4.e009048.56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025103115050509000_13.4.e009048.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0"},{"key":"2025103115050509000_13.4.e009048.58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020303","article-title":"CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025103115050509000_13.4.e009048.59","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2444701","article-title":"Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers","volume":"14","author":"Velasco-Sidro","year":"2025","journal-title":"Oncoimmunology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:05:17Z","timestamp":1761948317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,30]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/jitc-2024-009048"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009048","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}